103 related articles for article (PubMed ID: 27048113)
1. G12V Kras mutations in cervical cancer under virtual microscope of molecular dynamics simulations.
Chen XP; Xu WH; Xu DF; Fu SM; Ma ZC
Eur J Gynaecol Oncol; 2016; 37(1):69-74. PubMed ID: 27048113
[TBL] [Abstract][Full Text] [Related]
2. Synergy and anti-cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS-RGL1.
Hacisuleyman A; Erman B
Proteins; 2024 May; 92(5):665-678. PubMed ID: 38153169
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
Jiang W; Xiang L; Pei X; He T; Shen X; Wu X; Yang H
J Gynecol Oncol; 2018 Jan; 29(1):e4. PubMed ID: 29185262
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
5. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
6. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
7. Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling.
Pantsar T; Rissanen S; Dauch D; Laitinen T; Vattulainen I; Poso A
PLoS Comput Biol; 2018 Sep; 14(9):e1006458. PubMed ID: 30199525
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs.
Prakash P; Litwin D; Liang H; Sarkar-Banerjee S; Dolino D; Zhou Y; Hancock JF; Jayaraman V; Gorfe AA
Biophys J; 2019 Jan; 116(2):179-183. PubMed ID: 30616834
[TBL] [Abstract][Full Text] [Related]
9. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
[TBL] [Abstract][Full Text] [Related]
11. Bringing Structural Implications and Deep Learning-Based Drug Identification for
Mehmood A; Kaushik AC; Wang Q; Li CD; Wei DQ
J Chem Inf Model; 2021 Feb; 61(2):571-586. PubMed ID: 33513018
[TBL] [Abstract][Full Text] [Related]
12. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
13. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
14. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
Jones RP; Sutton PA; Evans JP; Clifford R; McAvoy A; Lewis J; Rousseau A; Mountford R; McWhirter D; Malik HZ
Br J Cancer; 2017 Mar; 116(7):923-929. PubMed ID: 28208157
[TBL] [Abstract][Full Text] [Related]
15. Computational Screening and Analysis of Lung Cancer Related Non-Synonymous Single Nucleotide Polymorphisms on the Human Kirsten Rat Sarcoma Gene.
Wang Q; Mehmood A; Wang H; Xu Q; Xiong Y; Wei DQ
Molecules; 2019 May; 24(10):. PubMed ID: 31117243
[TBL] [Abstract][Full Text] [Related]
16. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
17. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
[TBL] [Abstract][Full Text] [Related]
19. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
20. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Biernacka A; Tsongalis PD; Peterson JD; de Abreu FB; Black CC; Gutmann EJ; Liu X; Tafe LJ; Amos CI; Tsongalis GJ
Cancer Genet; 2016 May; 209(5):195-8. PubMed ID: 27068338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]